文 ｜ 秦培景 刘易 王冠然 侯苏洋 卿施典 任恒毅 白弘伟 田鹏 王涛 王子昂 上周关税等外部因素影响的高峰已过，国内政策表态增强投资者信心，市场风险偏好开始修复，综 合考虑前期回调幅度、政策及事件催化，本周建议关注四大主题，包括强催化期来临的AI+主题， 受益于国家内循环和关税反制措施的免税及农业主题，率先超跌反弹的北交所主题，外部限制加码 下的半导体自主可控主题。外部扰动开始边际缓和，关税等外部因素影响的高峰已过，但全球仍处 于衰退预期交易阶段，主题方面，建议聚焦自主可控主线，以及业绩确定性或订单确定性强、估值 水平相对低位的相关板块和资产。从主题环境来看，综合流动性指标和市场风格特征，预计高位主 题板块受风险偏好下行影响大。从催化因素分析上看，重点关注围绕"对等关税"的博弈进展，第 1 3 7届中国进出口商品交易会首次在第一期增设服务机器人专区，第三届新能源汽车创新技术及行 业发展论坛展现行业的技术突破。结合市场环境、催化因素以及综合量化指标研判，建议关注 AI+、免税及农业、北交所、半导体自主可控四大主题。我们在报告中还梳理了1 0个标的构成的主 题推荐组合供投资者参考。 及边境保护局（CBP）在官 ...

Core Viewpoint - The public fund industry achieved impressive performance in Q1 2025, driven by a structural market led by AI and robotics themes [1][2]. Group 1: Fund Performance - The fund performance leaderboard for Q1 2025 was dominated by robotics-themed funds, Beijing Stock Exchange funds, and Hong Kong stock funds [2]. - The top-performing fund, Penghua Carbon Neutral Theme A, managed by Yan Siqian, achieved a return of 60.26%, heavily investing in several robotics stocks [3][5]. - Other notable funds include Ping An Advanced Manufacturing Theme A and Yongying Advanced Manufacturing Smart Selection A, both exceeding 50% returns, also focusing on robotics [6]. Group 2: Robotics Theme Funds - Penghua Carbon Neutral Theme A's significant holdings included stocks like Beite Technology and Hechuan Technology, with Double Forest Co. seeing a year-to-date increase of 118.16% [3][6]. - Fund managers expressed optimism about the rapid production of humanoid robots and the investment opportunities in new materials and technologies [7]. - The focus on core components and AI perception in humanoid robots indicates a growing market potential, with significant room for technological advancement [7][8]. Group 3: Beijing Stock Exchange Funds - Beijing Stock Exchange funds also performed well, with notable returns from funds like CITIC Construction Investment and Huaxia, achieving returns of 38.98% and 37.45% respectively [9]. - These funds have successfully identified high-performing stocks within the Beijing Stock Exchange, such as Kelaite, which saw a remarkable increase of 136.01% [9]. Group 4: Hong Kong Stock Funds - Hong Kong stock funds regained attention, with funds like Huatai Hong Kong Advantage Selection and Zhongyin Hong Kong Medical achieving returns of 38.9% and 32.25% respectively [12]. - The performance of these funds was bolstered by significant gains in pharmaceutical stocks, with companies like Kelun Pharmaceutical and Rongchang Biological seeing increases of 78.08% and 64.58% [12]. - The manager of Huatai Hong Kong Advantage Selection highlighted the growing competitiveness of Chinese innovative drugs in the global market, projecting a significant increase in overseas licensing deals [12][13].

Investment Rating - The report does not explicitly state an investment rating for the industry or specific companies [18]. Core Insights - The report provides a detailed analysis of the performance of stocks listed on the North Exchange, highlighting significant fluctuations in stock prices across various sectors as of March 11, 2025 [7][8]. - The report includes a comparative analysis of the average trading volume and turnover rate on the North Exchange, indicating a growing interest in this market segment [6]. - The report identifies the top ten gainers and losers in the market, showcasing the volatility and potential investment opportunities within the North Exchange [7][8]. Summary by Relevant Sections - **Market Performance**: The North Exchange has shown varied performance with notable increases in certain stocks, such as 卓兆点胶 (29.99% increase) and 倍益康 (23.76% increase), while others like 立方控股 experienced significant declines (-18.34%) [7][8]. - **Trading Activity**: The total trading volume reached significant levels, with a turnover rate averaging around 16% as of the reporting date, indicating active market participation [6]. - **Sector Analysis**: The report includes a breakdown of price-to-earnings (PE) ratios across different sectors, providing insights into valuation trends and potential investment areas [12].